Immune-modulating ADCs represent a class of non-cytotoxic payloads receiving increased attention as the field looks to diversify ADC mechanisms beyond classical Topo1 and MMAE therapies.

Attend this workshop to cover the history of immune-stimulating therapies and the progress being made to make effective ADC payloads, alongside the emerging development of immune-modulating ADCs expanding applications outside of oncology.

Workshop highlights include:

• Overviewing the ISAC field to contextualize clinical learnings and the opportunity of ISACs as an alternative, non-cytotoxic ADC mechanisms
• Delving into TLR7/8 and STING agonist development to understand which immune-stimulating molecules make effective ADC payloads
• Assessing the emergence of immunesuppressing ADCs leveraging glucocorticoid mechanisms for ISAC applications outside of oncology